Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

22 Jul 2019

Abstract excerpt

Chimeric antigen receptor T (CAR-T) cell therapy is a cutting edge and potentially revolutionary new treatment option for cancer. However, there are significant limitations to its widespread use in the treatment of cancer. These limitations include the development of unique toxicities such as cytokine release syndrome (CRS) and neurotoxicity (NT) and limited expansion, effector functions, and anti-tumor activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31380838
DOI: 10.3791/59629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T CellsPMID 31380838Read ↗

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T CellsSemantic proximity Read ↗

RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokinesSemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor EfficacySemantic proximity Read ↗

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapySemantic proximity Read ↗

CRISPR/Cas9 edited tumor-associated immune cells in cancer immunotherapySemantic proximity Read ↗

Using CRISPR to enhance T cell effector function for therapeutic applicationsSemantic proximity Read ↗

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read ↗

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapySemantic proximity Read ↗

CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T CellsSemantic proximity Read ↗

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome EditingSemantic proximity Read ↗

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.